Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

BACKGROUND: The oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese ty...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Li, Chun-Jun, Liu, Xiao-Juan, Bai, Lian, Yu, Qian, Zhang, Qiu-Mei, Yu, Pei, Yu, De-Min
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050987/
https://ncbi.nlm.nih.gov/pubmed/24917890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1758-5996-6-69
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky